CLINICAL TRIALS PROFILE FOR RAZADYNE
✉ Email this page to a colleague
All Clinical Trials for RAZADYNE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00227994 ↗ | Acetylcholinesterase Inhibitors to Improve Cognitive Function and Overall Rehabilitation After a Stroke | Completed | National Institute of Mental Health (NIMH) | Phase 4 | 2003-04-01 | This study will evaluate the effectiveness of treatment with acetylcholinesterase inhibitors in improving cognitive function and overall rehabilitation in elderly stroke survivors. |
| NCT00227994 ↗ | Acetylcholinesterase Inhibitors to Improve Cognitive Function and Overall Rehabilitation After a Stroke | Completed | University of Pittsburgh | Phase 4 | 2003-04-01 | This study will evaluate the effectiveness of treatment with acetylcholinesterase inhibitors in improving cognitive function and overall rehabilitation in elderly stroke survivors. |
| NCT00232349 ↗ | Efficacy of Galantamine to Treat Schizophrenia | Terminated | Seattle Institute for Biomedical and Clinical Research | Phase 4 | 2005-02-01 | The purpose of this study was to determine if treatment with adjunctive galantamine is effective in the reduction of functional impairments in patients with schizophrenia and schizoaffective disorder. It was hypothesized that adjunctive galantamine would yield clinically significant improvements from baseline to end of study on a measure of quality of life and a measure of independent living skills. |
| NCT00348140 ↗ | Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease | Completed | GlaxoSmithKline | Phase 3 | 2006-07-12 | Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer's disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one's genetic makeup affects the response to the study drug. Clinical data suggesting that RSG may benefit AD patients was first seen in a small study performed at the University of Washington and then from a larger GSK study conducted in Europe and New Zealand. In the first study, subjects receiving RSG once daily for 6 months scored significantly better on 3 tests of memory and thought than those who did not receive RSG. In the GSK study, those that appeared to benefit most from treatment with RSG XR had a specific genetic pattern. They did not have the gene that caused them to produce the protein apolipoprotein E e4 (APOE e4). Subjects who have the APOE e4 gene may have two copies, one from each parent, or they may have only one APOE e4 gene meaning that they inherited either the APOE e2 or APOE e3 version of the gene, instead of APOE e4, from one of their parents. Subjects with one copy of the APOE e4 gene remained at their same level of thinking ability while those with two copies of the APOE e4 gene, continued to worsen during the 6-month treatment. The current study will more directly test the effectiveness or RSG XR on people who either have or lack the APOE e4 gene. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RAZADYNE
Condition Name
Clinical Trial Locations for RAZADYNE
Trials by Country
Clinical Trial Progress for RAZADYNE
Clinical Trial Phase
Clinical Trial Sponsors for RAZADYNE
Sponsor Name
